The Danish drugmaker said the drug will be available from today at prices starting from $149 per month for cash purchasers.

For the last three years, the world has obsessed over generative AI that can write and create. By the end of 2026, we'll see ...

Founded in 2014, Insilico finally pushed an IPO over the line last month, completing a much-oversubscribed listing on the ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an initial public offering (IPO) in Hong ...

Judge Lance Walker sided with the American Hospital Association (AHA) and other plaintiffs in the lawsuit, brought in a Maine ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept Therapeutics with a ...